

Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

SCIENTIFIC INDUSTRIES INC  
Form 10KSB  
September 29, 2003

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 10-KSB

(Mark One)

X ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934  
For the fiscal year ended JUNE 30, 2003

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934  
For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number 0-6658

SCIENTIFIC INDUSTRIES, INC.  
(Name of Small Business Issuer in Its Charter)

DELAWARE 04-2217279  
(State or Other Jurisdiction of (I.R.S. Employer  
Incorporation or Organization) Identification No.)

70 ORVILLE DRIVE, BOHEMIA, NEW YORK 11716  
(Address of principal executive offices) (Zip Code)

Issuer's telephone number (631) 567-4700

Securities registered under Section 12(b) of the Exchange Act:

Title of each class	Name of each exchange on which registered
None	None

Securities registered under Section 12(g) of the Exchange Act:

COMMON STOCK, PAR VALUE \$.05 PER SHARE  
(Title of Class)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [ x ] No [ ]

Check if there is no disclosure of delinquent filers in response to Item 405 of Regulation S-B not contained in this form, and no disclosure will be contained, to the best of registrant's knowledge, in the definitive proxy or information statements incorporated by

## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

reference in Part III of this Form 10-KSB or any amendment to this Form 10-KSB. [ X ]

Issuer's revenues for its most recent fiscal year. \$3,257,100

The aggregate market value of the voting stock held by non-affiliates computed by reference to the average bid and asked prices of such stock, as of August 29, 2003 is \$707,200.

The number of shares outstanding of the issuer's common stock, par value \$.05 per share ("Common Stock") as of August 29, 2003 is 960,541 shares.

### DOCUMENTS INCORPORATED BY REFERENCE

None.

Transitional Small Business Disclosure Format (check one):

Yes [ ] No [ X ]

### PART I

#### ITEM 1. DESCRIPTION OF BUSINESS.

**Forward Looking Statements.** The Company and its representatives may from time to time make written or oral forward-looking statements with respect to the Company's annual or long-term goals, including statements contained in its filings with the Securities and Exchange Commission and in its reports to stockholders.

The words or phrases "will likely result," "are expected to," "will continue to," "is anticipated," "estimate," "project" or similar expressions identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical earnings and those presently anticipated or projected. Readers are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date made.

**General.** Scientific Industries, Inc., a Delaware corporation (the "Company"), formed in 1954, designs, manufactures, and markets a variety of laboratory equipment. The Company's products are generally used for research purposes in research laboratories in or used by universities, hospitals, pharmaceutical companies, clinics, medical device manufacturers and other related industries. The Company's products are generally distributed and marketed through an established network of domestic and foreign laboratory equipment distributors. The Company also markets its products through attendance of industry trade shows, trade publication advertising, brochures and catalogs, independent sales representatives, and its own web site.

#### Products.

**Vortex Mixers** - The Company's primary product is the Vortex-Genie (registered trademark) 2 Mixer and related accessories. The vortex mixer is used to mix the contents of test tubes, beakers, and other various containers by placing such containers on a rotating cup or other

## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

attachments which cause the contents to be mixed at varying speeds. Sales of the Vortex-Genie 2 Mixer represented approximately 86% of the Company's revenues for the year ended June 30, 2003 ("fiscal 2003") as compared with 92% of the Company's revenues for the year ended June 30, 2002 ("fiscal 2002").

The Company recently introduced products that perform similar functions and complement the Vortex Mixer product line - the Vortex-Genie (registered trademark) 1 Touch Mixer, Vortex-Genie (registered trademark) 2T Timed Mixer, and Disruptor Genie (trademark) Cell Disruptor. All three products have been well accepted by the Company's distributors and end users. Although revenues from these products only represented approximately 5% of total revenues in fiscal 2003, which was the second year of their production, such sales were three times the sales from their initial year of introduction. The Company anticipates a further increase in sales of these products in future periods.

Rotators/Rockers and Incubators - The Company also designs and manufactures the Roto-Shake Genie registered trademark, which is a patented benchtop multi-purpose rotator/rocker used to rotate and rock a wide variety of containers which are magnetically attached to the unit's magnetized platform. In addition, the Company produces the Enviro-Genie (registered trademark) Refrigerated Incubator and the BioReactor Genie (trademark) Cell Culture Chamber (introduced during fiscal 2003), which are multi-functional benchtop environmental chambers designed to perform various functions under controlled environmental conditions of temperature. During fiscal 2003, the Company also introduced the Bag Rotator, a product that mixes transfer packs and other sealed bags for the clinical market.

Product Development. The Company designs and develops substantially all the products it sells. Its personnel formulate plans and concepts for new products and improvements or modifications to existing products. It also engages outside consultants to augment its capabilities in such areas as industrial design. The Company is currently working on the development of several new products, some of which it anticipates will be introduced during fiscal year 2004. The Company assembles its products at its factory using components purchased from various domestic and international sources.

Marketing. Commencing in January 2003, the Company substantially increased its marketing efforts and expenditures under its revised strategy for sales growth with: (i) the employment of a Director of Sales and Marketing; (ii) the entry into a long-term agreement providing for a substantial increase in the services of its outside marketing consultant, who earlier had been a marketing employee of the Company's principal distributor and who was elected a Director of the Company at the Annual Meeting of Stockholders in November 2002, and (iii) an expanded promotion and advertising program. In addition, the Company engaged several independent sales representatives during fiscal 2003 for marketing and selling certain products.

Raw Materials. The Company currently manufactures its products from readily available components supplied by various independent contractors, and does not rely on any one supplier, except as to a few components where it is not practicable to have multiple suppliers but alternative suppliers are available.

## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

Patents, Trademarks, Licenses and Franchises. The Company holds several United States patents relating to existing products. It licenses one of its patents, a patent on a utilitarian feature of its Vortex-Genie 2 Mixer on a non-exclusive royalty-free basis to Henry Troemner, LLC, ("Troemner"), under a settlement agreement dated December 1, 1999. This license expires on November 2, 2005, the expiration date of the patent. The Company's patent for the TurboMix (trademark), an attachment to the existing Vortex-Genie 2 Mixer, expires in September 2015. Its patent on the Roto-Shake Genie expires in July 2016. During fiscal 2003, the Company applied for a new patent and filed several trademark applications, all of which are currently pending. The Company intends to apply for additional patents and trademarks, when appropriate, for technology, products, and marks which it considers important for the protection of its business. No assurance can be given that any patent or trademark application will result in the issuance of a patent or trademark, or if granted, will provide effective protection.

The Company has various proprietary marks including Vortex-Genie (REGISTERED TRADEMARK), Disruptor Genie (trademark), MagStir Genie (trademark), BioReactor Genie (trademark), TurboMix (trademark), Roto-Shake Genie (REGISTERED TRADEMARK), Genie (trademark), and Enviro-Genie (TRADEMARK), each of which it considers important to the success of the related product.

Foreign Sales. The Company's foreign sales to various distributors outside the United States (principally Asia and Europe) accounted for approximately 48.6% of the Company's net sales for fiscal 2003 and 44.0% for fiscal 2002. Such sales are paid in United States dollars and are therefore not subject to risks of currency fluctuation, foreign duties and customs.

Seasonality. The Company does not consider its business to be seasonal.

Major Customers. Sales, predominantly of the Vortex-Genie 2 Mixer, to two of the company's customers, each a major distributor, represented in the aggregate approximately 42% of net sales for fiscal 2003 and 43% for fiscal 2002. The loss of either customer or a material reduction in their purchases, as experienced during fiscal 2003, could have a material adverse effect upon the operating results of the Company. Please refer to the "Risk Factors" section of this report for further discussion and additional information.

Backlog. The Company's backlog is not significant because the Company's current line of products is comprised of standard catalog items. The typical lead time for order fulfillment is approximately two weeks or less.

Competition. Most of the Company's competitors are substantially larger and have greater financial, production and marketing resources than the Company. Competition is generally based upon price, quality, technical specifications, and product recognition and acceptance. The Company is a dominant factor in the market for vortex mixers in the United States and is widely recognized in the international vortex mixers market.

In the general area of laboratory equipment, the Company's major competitors are Troemner, Barnstead/Thermolyne Corporation, a

## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

subsidiary of Sybron International, IKA-Werke GmbH & Co. KG, a German company, and Heidolph Instruments GmbH, a German company. Since the Company's products are primarily sold through distributor catalogs, the Company relies heavily on the distributors' decisions as to which products they include in their catalogs.

Research and Development. In connection with the development of new products, the Company incurred research and development expenses of \$292,300 during fiscal 2003 compared to \$289,600 during fiscal 2002. The Company expects to continue investing in research and development activities in fiscal year 2004, principally for the purpose of increased product diversification.

Government and Environmental Regulation. The Company's products and claims with respect thereto have not required approval of the Food and Drug Administration or any other government approval. The Company's manufacturing operations, like those of the industry in general, are subject to numerous existing and proposed, if adopted, federal, state, and local regulations to protect the environment, to establish occupational safety and health standards and to cover other matters. The Company believes that its operations are in compliance with existing laws and regulations and the cost to comply is not significant to the Company.

Employees. As of August 29, 2003, the Company employed 22 persons of which 19 were full-time. None of the Company's employees are represented by any unions.

### RISK FACTORS

In connection with the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, important risk factors are identified below that could affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed with respect to such future periods in any current statements. The Company undertakes no obligation to publicly revise any forward-looking statements to reflect future events or circumstances.

### THE COMPANY OFFERS A LIMITED NUMBER OF PRODUCTS WITH SALES OF ONE PRODUCT ACCOUNTING FOR A SUBSTANTIAL PORTION OF ITS REVENUES

The Company currently offers for sale a limited number of products, with sales of its Vortex-Genie 2 Mixer and accessories related thereto accounting for approximately 86% of the Company's sales for fiscal 2003 and 92% for fiscal 2002. In the past few years, there have been new entrants into the vortex-mixer market. Their mixers are being aggressively marketed by the same distributors that offer the Company's products. In January 2002, the Company's principal distributor replaced its private label vortex mixer, which the Company had supplied to them for many years, with a competitive mixer. Sales to this distributor accounted for approximately 26.6% and 33.0% of the Company's sales for fiscal 2003 and fiscal 2002, respectively. Although the Company still sells the Vortex-Genie 2 Mixer, which continues to be included in the distributor's catalog, under the Company's own brand, the unit sales to the distributor for fiscal 2003 were lower by 28% from sales for fiscal 2002. The Company expects to reduce the sales price of the Vortex-Genie 2 to the

## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

distributor at its request commencing in October 2003. No assurance can be given that the Company will be able to increase or maintain its current level of sales of the Vortex-Genie 2 Mixer or the operating margin derived therefrom.

THE COMPANY'S ABILITY TO GROW AND COMPETE EFFECTIVELY IS IN PART DEPENDENT ON ITS ABILITY TO DEVELOP AND EFFECTIVELY MARKET NEW PRODUCTS

During the past five years, the Company has pursued a program to develop and market new laboratory equipment with a view to increasing its revenues and reducing its dependence on the Vortex-Genie 2 Mixer. Pursuant to the program, the Company first developed and introduced the Roto-Shake Genie rotator/rocker and then the Enviro-Genie refrigerated incubator. During fiscal 2002, the Company began selling three new products which generally target the vortex mixer market - Vortex-Genie 1 Touch Mixer, Vortex-Genie 2T Timed Mixer, and the Disruptor Genie Cell Disruptor.

Revenues derived from products other than the Vortex-Genie 2 and its accessories amounted to \$423,600 and \$277,300, respectively, for fiscal 2003 and fiscal 2002. The Company historically has relied primarily on its distributors and their catalogs to market its products. Accordingly, it may be at least 24 to 36 months between the completion of development of a product and the distribution of the catalog in which it is first offered. The Company has recently expanded and revised its marketing program including hiring a new Director of Sales and Marketing and engaging several independent sales representatives to handle certain products. No assurance can be made that the amounts allocated by the Company for its development and marketing program are sufficient for such purpose, that any particular product will be included in a distributor's catalog or that any significant sales will result from the expanded efforts.

THE COMPANY IS A SMALL PARTICIPANT IN ITS HIGHLY COMPETITIVE INDUSTRY

Although the Company's principal product, the Vortex-Genie 2 Mixer, has been widely accepted, the Company is an insignificant factor in the highly competitive laboratory products industry. The Company's net sales for fiscal 2003 and fiscal 2002 were \$3,257,100 and \$3,457,300, respectively. Its principal competitors are substantially larger and have much greater financial, production and marketing resources than the Company.

THE COMPANY'S ABILITY TO COMPETE DEPENDS IN PART ON ITS ABILITY TO SECURE AND MAINTAIN PROPRIETARY RIGHTS TO ITS PRODUCTS

The Company's ability to compete depends in part on its ability to secure and maintain proprietary rights to its products. The Company holds a design patent expiring in November 2005 on a feature of its Vortex-Genie 2 Mixer, its principal product. It holds a patent on an attachment to that product which expires in September 2015 and on another product which expires in July 2016. During fiscal 2003, the Company applied for an additional patent, and intends to apply for additional patents on new products.

There can be no assurance that it will be successful in obtaining additional patents, that any patent issued to the Company provides or will provide the Company with competitive advantages or will not be challenged by third parties or that the patents of others will not prevent the commercialization of products developed by the Company. Furthermore, there can be no assurance that others will not independently develop similar products or design around the Company's patents. Any of the foregoing activities could

## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

have a material adverse effect on the Company.

Moreover, there is no assurance that the enforcement by the Company of its patent rights will not result in substantial litigation costs, as it did in fiscal 2000 in the defense of its proprietary claim with respect to its Vortex-Genie 2 Mixer.

### THE COMPANY HAS LIMITED MANAGEMENT RESOURCES

The Company's operations were managed until August 29, 2002 by Mr. Lowell A. Kleiman, as President and Chief Executive Officer, Ms. Helena Santos, as its Vice President - Engineering. On August 29, 2002, the employment of Mr. Kleiman was discontinued and the Company appointed Ms. Santos as President, Chief Executive Officer and Treasurer to supervise the Company's operations and administration; and Mr. Nichols as Executive Vice President and Secretary to supervise engineering and product development. No assurance can be given that the change will not have a materially adverse effect on the Company's operations or financial condition. Any material expansion of the Company's operations could place a significant additional strain on the Company's limited management resources. Furthermore, the loss of either Ms. Santos or Mr. Nichols in the absence of an equally qualified successor could be materially adverse to the Company's results and financial condition.

### THE COMMON STOCK OF THE COMPANY IS THINLY TRADED AND IS SUBJECT TO VOLATILITY

The Common Stock of the Company is traded on the Over-the-Counter Bulletin Board and, historically, has been thinly traded. As of August 29, 2003, there were only 960,541 shares of Common Stock of the Company outstanding, of which 315,815 shares are held by the directors and officers of the Company. There have been a number of trading days during fiscal 2003 on which no trades of the Company's Common Stock were reported. Accordingly, the market price for the Common Stock is subject to great volatility.

### ITEM 2. DESCRIPTION OF PROPERTY.

The Company's executive offices and manufacturing facilities comprising approximately 25,000 square feet are located at 70 Orville Drive, Bohemia, New York 11716 and are held pursuant to a lease which expires on December 31, 2004, and provides for a minimum annual rental of \$239,800 for the year ending June 30, 2004. The leased facilities are suitable and adequate for such use. In the opinion of management, the property is adequately covered by insurance. See Note 8 to the Financial Statements in Item 7 for further information about the Company's lease obligations.

### ITEM 3. LEGAL PROCEEDINGS.

The Company is not a party to any pending legal proceedings. However, a financial advisor employed by the Company pursuant to an engagement letter that was not extended by the Company beyond its expiration date of March 31, 2002 asserted in April 2002 a claim against the Company in the amount of \$125,000 for alleged services rendered to the Company that were alleged to be outside the scope of the letter. The Company denies engaging the financial advisor for any services outside the scope of the engagement letter or that any amount is owing to the advisor. The Company's counsel has advised the Company that based on its review of the engagement letter and the Company's denial, it is unlikely that the

## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

financial advisor will prevail if it institutes a legal proceeding.

### ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

No matters were submitted to a vote of security holders during the fourth quarter of fiscal 2003.

## PART II

### ITEM 5. MARKET FOR THE REGISTRANT'S COMMON STOCK AND RELATED STOCKHOLDER MATTERS.

(a) The Company's Common Stock is traded in the over-the-counter market. The following table sets forth the low and high bid quotations for each quarter of fiscal 2003 and fiscal 2002, as reported by the National Association of Securities Dealers, Inc. Electronic Bulletin Board. Such quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not represent actual transactions:

For Fiscal Quarter Ended:	Low Bid	High Bid
09/30/01	1.30	1.55
12/31/01	1.25	2.40
03/31/02	1.30	2.40
06/30/02	1.20	1.60
09/30/02	1.10	1.80
12/31/02	1.05	1.50
03/31/03	1.05	1.15
06/30/03	1.05	1.15

(b) There were, as of August 29, 2003, 872 record holders of the Company's Common Stock.

(c) The Company has not paid any dividends but is not subject to any agreement which prohibits or restricts the Company from paying dividends on its Common Stock.

### ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Management's Discussion and Analysis of Financial Condition and Results of Operations and other portions of this report contain forward-looking statements that involve risks and uncertainties. Actual results could differ materially from those anticipated by the forward-looking information. Factors that may cause such differences include, but are not limited to, product demand, market acceptance and other factors discussed elsewhere in this report. This Management's Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with our financial statements and the related notes included elsewhere in this report.

Overview. Net sales of \$3,257,100 for fiscal 2003 were 5.8% lower than fiscal 2002's net sales of \$3,457,300. Management believes that sales for the 2003 fiscal year were negatively affected by increased competition experienced in sales of mixers that compete with the Vortex-Genie 2 Mixer, and general economic conditions, including continuing weakness in European markets. We have been negatively affected by the decision, in January 2002, of our principal distributor, which is the leading distributor of U.S. laboratory



## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

equipment, to replace its private label vortex mixer with a competitive unit. Sales to this distributor, primarily the Company's Vortex-Genie 2 Mixer and related accessories, accounted for 26.6% and 33.0%, respectively, of the Company's net sales for fiscal 2003 and fiscal 2002. While Management believes that the offer by the distributor of its private label vortex mixer in competition with the Company's Vortex-Genie 2 Mixer, coupled with a reduction in the unit selling price commencing in October 2003, will continue to negatively impact the Company's sales, Management also believes that sales of the Company's mixer to the second largest U.S. laboratory equipment distributor will increase because of the recent inclusion of our products in its new catalog. The Company also expects to effect increased sales through increasing sales of its recent product additions to the vortex mixer

line, namely the Vortex-Genie 1, Vortex-Genie 2T and Disruptor Genie, and increased promotion and advertising.

The Company's profitability for fiscal 2003 was negatively impacted by the lower sales and \$72,400 incurred with respect to a proxy contest as to the election of Directors and the Company's 2002 Stock Option Plan instituted unsuccessfully by the Company's former Chairman of the Board, Chief Executive Officer and President (the "Former CEO") in connection with the 2002 Annual Meeting of Stockholders. However, the Company benefitted from lower general and administrative expenses as a result of the termination of its compensation and benefit obligations to the Former CEO whose employment ended on August 29, 2002, partially offset by increases in the salaries of its new Chief Executive Officer who had been Vice President, Contoller and Secretary and its Executive Vice President who had been Vice President - Engineering.

The Company's selling expenses increased in fiscal 2003 because as of January 2003, the Company substantially increased its marketing efforts and expenditures under its revised strategy for sales growth with: (i) the employment of a Director of Sales and Marketing; (ii) the entry into a long-term agreement providing for a material increase in the services of its marketing consultant, who earlier had been a marketing employee of the Company's principal distributor and who was elected a Director of the Company at the Annual Meeting of Stockholders in November 2002, and (iii) an expanded promotion and advertising program. The Company believes that this additional expenditure and commitment will prove beneficial.

Results of Operations. Net sales for fiscal 2003 were \$3,257,100, a decrease of \$200,200 (5.8%) compared to net sales of \$3,457,300 for fiscal 2002. As previously discussed, the lower sales were mostly due to lower unit sales of the Vortex-Genie 2 Mixer as a result of competition from a private label mixer offered by the Company's largest customer and general economic conditions. However, the decrease in Vortex-Genie 2 sales was partially offset by an increase in sales from other products. Sales (excluding accessories) of new products, principally the Roto-Shake Genie, Enviro-Genie, Disruptor Genie, Vortex-Genie 2T, and Vortex-Genie 1, increased 52.3% to \$423,600 for fiscal 2003 compared to \$277,300 for fiscal 2002. The gross profit percentage for fiscal 2003 of 41.2% exceeded the gross profit percentage of 40.8% for fiscal 2002, mostly as a result of a reduction in factory labor personnel, which did not affect productivity.

## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

General and administrative ("G&A") expenses were \$791,700 for fiscal 2003, a decrease of \$63,200 (7.4%) compared to \$854,900 in fiscal 2002 mostly as a result of the discontinuation in August 2002 of the compensation and benefits paid to the Former CEO, partially offset by \$72,400 of expenses incurred with respect to the proxy contest previously discussed in this report. Fiscal 2002's G&A expenses reflected \$62,900 in advisory fees incurred under a financial advisory agreement, which expired March 31, 2002.

Selling expenses for fiscal 2003 increased \$37,600 (21.1%) to \$216,000 compared to \$178,400 for fiscal 2002 as a result of the Company's expansion of its sales and marketing efforts. During fiscal 2003, the Company hired a Director of Sales and Marketing and significantly increased the services of its outside marketing consultant as well as its promotional and advertising activity.

Research and development expenses for fiscal 2003 were \$292,300 compared to \$289,600 for fiscal 2002. The small increase, despite increased development efforts, was the result of the reduction of in-house engineering personnel and engagement of a lower cost outside engineering firm.

The Company reflected an income tax benefit of \$11,500 for fiscal 2003 compared to income tax expense of \$28,300 for fiscal 2002, mainly as a result of the recognition of tax credits.

Liquidity and Capital Resources. The Company's cash and cash equivalents, and short-term investments increased from \$778,700 at the end of fiscal 2002 to \$803,000 at the end of fiscal 2003. The Company's working capital increased \$143,600 to \$1,675,000 from \$1,531,400. The increase in working capital was mostly due to certain long-term investments becoming current assets during the current year. Accounts receivable were higher as of the end of fiscal 2003 compared to fiscal 2002 due to the higher sales for the last month of fiscal 2003 than for June 2002. The reduction in inventories as of the end of fiscal 2003 compared to fiscal 2002 was the result of lower work in process and finished goods balances.

The Company has available a secured bank line of credit of \$200,000 with North Fork Bank which expires on November 1, 2003 and carries interest at prime plus 1%. The Company will seek to extend the credit line which has never been utilized.

Management believes that it will be able to meet its cash flow requirements during the next fiscal year from its available financial resources which are anticipated to include future cash generated from operations, its cash and cash equivalents and investments, and if required, the credit line.

Capital Expenditures. During fiscal 2003, the Company did not incur any material capital expenditures. The Company does not expect to incur in the normal course of business any material capital expenditures during fiscal 2004. It is anticipated, as in past fiscal years, that capital expenditures, if any, will be funded from the Company's operations or available working capital.

### ITEM 7. FINANCIAL STATEMENTS.

The Financial Statements required by this item are attached hereto on pages F1-F18.

## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

Not applicable.

### PART III

ITEM 9. DIRECTORS, EXECUTIVE OFFICERS; COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT.

#### DIRECTORS

The Company has five Directors. The Directors of the Company are elected to two-year staggered terms. The terms of the Directors currently expire at the annual meeting of stockholders of the Company to be held as follows: the next annual meeting which will follow the fiscal year ended June 30, 2003 as to two Directors (Messrs. Borden and Segasture, Class A), the annual meeting which follows fiscal year ending June 30, 2004 as to one Director (Mr. Kesselman, Class B), and the annual meeting which follows fiscal year ending June 30, 2005 as to two Directors (Messrs. Cremonese and Knowles, Class C). Mr. Kesselman is Chairman of the Board. The name, principal occupation for the last five years, selected biographical information and period of service as a director of the Company of each Director are set forth in this section.

Arthur M. Borden, Esq. (age 83), a Director since 1974, has been counsel to the law firm of Katen Muchin Zavis Rosenman (formerly Rosenman & Colin) during the past five years.

Joseph G. Cremonese (age 68), a director since November 2002, has been a marketing consultant to the Company since 1996, with his marketing consulting duties substantially increased as of January 2003 under a new two-year agreement with the Company. Mr. Cremonese has been since 1991, President of Laboratory Innovation Company, Ltd., which is a vehicle for technology transfer and consulting services for companies engaged in the production and sale of products for science and biotechnology. Since March 2003, Mr. Cremonese has been a director and consultant of Proteomics, Inc., a producer of recombinant proteins for medical research. Mr. Cremonese had been, prior to 1991, employed by Fisher Scientific (the Company's largest customer).

Joseph I. Kesselman (age 77), a Director since 1961 and Chairman of the Board since August 29, 2002, is a consultant to various corporations, and a director of Nuclear and Environmental Protection Inc., Perrot Duval Holding S.A. (A Swiss public company), Hopare Holding, S.A. (A Swiss company), and Infranor Inc., a developer and manufacturer of servo systems.

Roger B. Knowles (age 77), a Director since 1965, is retired and during the past five years has been involved in liquidating various real estate and manufacturing concerns.

James S. Segasture (age 67), a Director since 1991, has been a private investor since February 1990.

#### BOARD COMMITTEES

During the year, the Board of Directors appointed Messrs. Joseph I.

## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

Kesselman and James S. Segasture as the sole members of the Company's Stock Option Committee to serve at the discretion of the Board and to administer the Company's 2002 Stock Option Plan.

The Company does not currently have any other committees.

### EXECUTIVE OFFICERS

On August 29, 2002, after the failure of the Company and Mr. Lowell A. Kleiman to negotiate an extension of his employment agreement which expired on June 30, 2002, the employment of Mr. Kleiman was discontinued and the Company appointed two executive officers, Helena R. Santos as President, Chief Executive Officer and Treasurer to supervise operations and administration, and Robert P. Nichols as Executive Vice President and Secretary to supervise product development and engineering.

Helena R. Santos, CPA (age 39) has been employed by the Company since 1994, and served, prior to her appointment to her current offices, as Vice President, Controller from 1997 and Secretary from May 2001. Prior to joining the Company, she was an internal auditor with a major defense contractor from March 1991 to April 1994. She had been previously employed in public accounting.

Robert P. Nichols (age 42) has been employed by the Company since February 1998, and served, prior to his recent appointments, as Vice President, Engineering from May 2001. Prior to joining the Company, he was an Engineer Manager with Bay Side Motion Group, a precision motion equipment manufacturer from January 1996 to February 1998.

### SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

The Company believes that, for the year ended June 30, 2003, all filing requirements of Section 16(a) of the Securities Act of 1934, as amended, applicable to its officers, directors and 10% stockholders were complied with timely.

### ITEM 10. EXECUTIVE COMPENSATION.

The following table summarizes all compensation paid by the Company to its then Chief Executive Officer and President with respect to each of the three fiscal years ended June 30, 2003. No other executive officer earned in excess of \$100,000 in any of such fiscal periods.

#### SUMMARY COMPENSATION TABLE

##### ANNUAL COMPENSATION

Name	Year	Salary	Bonus	All Other Compen- sation
Helena R. Santos	2003	\$ 76,000	\$ -	\$ -
Lowell A. Kleiman (1)	2003	\$ 53,300	\$ -	\$ 19,500 (2)
Lowell A. Kleiman	2002	\$ 160,000	\$ -	\$ -
Lowell A. Kleiman	2001	\$ 160,000	\$ -	\$ -

## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

(1) Mr. Kleiman's employment terminated on August 29, 2002 at which time Ms. Santos was appointed Chief Executive Officer and President.

(2) Represents accrued benefits paid to Mr. Kleiman upon his termination.

### OPTION GRANTS IN LAST FISCAL YEAR

#### Individual Grants

Name	Number of Securities Underlying Options Granted (#)	% of Total Options Granted to Employees in Fiscal Year	Exercise Price (\$/Sh)	Expiration Date
Robert P. Nichols	5,000	71	1.25	10/20/12

### AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR AND FY-END OPTION VALUES

Name	Shares of Common Stock Acquired On Exercise (#)	Value Realized (\$) (1)	Number of Securities Underlying Unexercised Options at FY-End (#) Exercisable/ Unexercisable	Value of Unexercised in-the-money Options at FY-End (\$) Exercisable/ Unexercisable (1)
Helena R. Santos	1,000	300	24,000/0	1,100/0

(1) Calculated by multiplying the number of shares of Common Stock subject to options by the difference between the market price and exercise price, per share, on June 30, 2003. Of the 24,000 unexercised options, only 9,000 options were in-the-money at June 30, 2003.

#### Employment Agreements

Ms. Helena R. Santos and Mr. Robert P. Nichols are employed by the Company pursuant to two-year employment contracts commencing January 2003. Each employment contract provides for the individual's full time employment as a senior executive with the Company for the period ending December 31, 2004. The agreements provide for a base salary through December 31, 2003 at the per annum rate of \$100,000 and \$95,000, respectively, with the base salary for the following year to be determined by the Board of Directors but to be not less than the prior year's base salary and for annual bonuses which may be paid with respect to their performance to be at the discretion of the Board of Directors. Each agreement contains non-competition and confidentiality covenants.

#### DIRECTORS' COMPENSATION

The Company currently pays each non-employee Director a quarterly retainer of \$750 and a fee of \$500 for each meeting attended, plus reimbursement for out-of-pocket expenses incurred in connection with attendance at board meetings in the amount of \$50 or the Director's itemized expenses, whichever is greater. The Company also agreed that commencing March 2003, it would pay its Chairman of the Board, Mr.

## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

Joseph I. Kesselman, a monthly fee of \$500 for his services in such capacity in addition to the quarterly fee. During fiscal 2003, the Company paid fees in the aggregate amount of \$36,100 to non-employee Directors.

On February 11, 1992, before the adoption of the Company's 1992 Stock Option Plan ("1992 Plan"), the Company issued to each of its four non-employee directors, Messrs. Arthur M. Borden, Joseph I. Kesselman, Roger B. Knowles and James S. Segasture, ten year non-qualified options to purchase, at a price of \$0.35 per share, 12,000

shares of Common Stock, which were exercisable in three annual installments. All 48,000 options were exercised by the directors prior to June 30, 2003.

The Company's 1992 Stock Option Plan ("1992 Plan") authorized the grant of options to purchase 3,000 shares of Common Stock at the then fair market value to each non-employee director who was on the Board of Directors on the first business day of each March, in 1993, 1994, 1995, and 1996. In addition, in December 1997, the Board of Directors approved annual grants under the 1992 Plan beginning in December 1997 of options to purchase 4,000 shares of Common Stock for each non-employee director exercisable at the fair market value on the date of grant. Accordingly, as of June 30, 2003, the Company had granted under the 1992 Plan in the aggregate to the foregoing four non-employee Directors options to purchase 128,000 shares of Common Stock, or options to purchase 32,000 shares of Common Stock for each. The fair market value per share of Common Stock on the dates of grant ranged from \$0.50 for options granted in 1993 to \$2.40 in 2002. All options were immediately exercisable, except for 834 shares each (an aggregate of 3,336 shares) under the options granted on December 31, 2000 which became available and exercisable on July 1, 2001. As of June 30, 2003, options with respect to 88,000 shares had been exercised by the Directors of which 40,000 were under the 1992 Plan.

Under the Company's 2002 Stock Option Plan ("2002 Plan"), which was approved by the Company's stockholders at the 2002 Annual Meeting of Stockholders, none of current directors, except for Mr. Joseph G. Cremonese who became a newly elected Director at the 2002 Annual Meeting, are eligible to receive option grants.

### ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT.

The following table sets forth, as of year end, the number of shares of Common Stock beneficially owned by (i) the persons known to the Company to be the owners of more than 5% of the Common Stock, (ii) each director of the Company, (iii) each named executive officer of the Company, and (iv) all directors and executive officers as a group. Unless otherwise indicated below, the address for each director and executive officer is c/o Scientific Industries, Inc., 70 Orville Drive, Bohemia, New York 11716.

Name	Amount and Nature of Beneficial Ownership	% of Class
-----	-----	-----
Lowell A. Kleiman 16 Walnut Street Glen Head, NY 11545	139,581	14.5%

## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

Arthur M. Borden	62,540 (1)	6.3%
Joseph G. Cremonese	5,000 (2)	.5%
Joseph I. Kesselman	63,520 (3)	6.4%
Roger B. Knowles	91,705 (4)	9.3%
James S. Segasture	177,250 (5)	18.4%
Robert P. Nichols	27,800 (6)	2.8%
Helena R. Santos	25,000 (7)	2.5%

All directors and executive officers as a group (7 persons) 452,815 (8) 41.3%

- (1) Includes 26,000 shares issuable upon exercise of options.
- (2) Owned jointly with his wife.
- (3) Includes 29,000 shares issuable upon exercise of options and 735 shares of Common Stock owned jointly with his wife.
- (4) Includes 44,158 shares owned by his wife, and 1,337 shares owned by a trust of which he is a trustee, beneficial ownership of which is disclaimed by him.
- (5) Includes 4,000 shares issuable upon exercise of options, and 493 shares owned by his wife.
- (6) Includes 25,000 shares issuable upon exercise of options.
- (7) Includes 24,000 shares issuable upon exercise of options.
- (8) Includes 137,000 shares issuable upon exercise of options.

### ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS.

In January 2003, the Company entered into a consulting agreement with Mr. Joseph G. Cremonese, who was elected a Class C Director at the Annual Meeting of Stockholders in 2002 and has been providing the Company with consulting services as an independent marketing consultant for approximately seven years. The consulting agreement provides that Mr. Cremonese and his affiliate, Laboratory Innovation Company, Ltd. will, at the request of the Company, render for the period January 1, 2003 through December 31, 2004 marketing consulting services of at least 80, but not more than 96, days per year at the rate of \$450 per day with a monthly cap of \$3,000, with the Company's obligation reduced to the extent the consulting services are less than 80 days for the 12 month period. The agreement contains confidentiality and non-competition covenants. During fiscal 2003, the Company paid Mr. Cremonese an aggregate of \$25,300 for his consulting services to the company.

### ITEM 13. EXHIBITS AND REPORTS ON FORM 8-K.

#### (a) Exhibits

The exhibits to this report are listed in the Exhibit Index at the end of this report.

#### (b) Reports on Form 8-K

There were no reports on Form 8-K filed during the last quarter of fiscal 2003 covered by this report with the Commission.

SIGNATURES

## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SCIENTIFIC INDUSTRIES, INC.  
(Registrant)

/s/ Helena R. Santos  
-----

Helena R. Santos  
President, Chief Executive Officer and Treasurer  
Principal Executive, Financial and Accounting  
Officer

Date: September 29, 2003

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Name -----	Title -----	Date -----
/s/ Arthur M. Borden Arthur M. Borden	Director	September 26, 2003
/s/ Joseph G. Cremonese Joseph G. Cremonese	Director	September 26, 2003
/s/ Joseph I. Kesselman Joseph I. Kesselman	Director (Chairman)	September 26, 2003
/s/ Roger B. Knowles Roger B. Knowles	Director	September 26, 2003
/s/ James S. Segasture James S. Segasture	Director	September 26, 2003

### EXHIBIT INDEX

Exhibit Number	Description
3	Articles of Incorporation and By-Laws:
3(a)	Certificate of Incorporation of the Company as amended. (Filed as Exhibit 1(a-1) to the Company's General Form for Registration of Securities on Form 10 dated February 14, 1973 and incorporated by reference thereto.)
3(b)	Certificate of Amendment of the Company's Certificate of



## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

Incorporation, as filed on January 28, 1985. (Filed as Exhibit 3(a) to the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 1985 and incorporated by reference thereto.)

- 3(c) By-Laws of the Company, as restated and amended. (Filed as Exhibit 3(ii) to the Company's Current Report Form 8-K filed on January 6, 2003) and incorporated by reference thereto.
- 4 Instruments defining the rights of security holders:
  - 4(a) 2002 Stock Option Plan (Filed as Exhibit 99-1 to the Company's Current Report on Form 8-K filed on November 25, 2002 and incorporated by reference thereto).
- 10 Material Contracts:
  - 10(a) Letter of Intent to exercise 5-year option under the Company's lease for its offices and manufacturing facilities. (Filed as Exhibit 10 to the Company's annual report on Form 10-K for the fiscal year ended June 30, 1999 and incorporated by reference thereto).
  - 10(b) Employment Agreement dated January 1, 2003, by and between the Company and Ms. Santos (Filed as Exhibit 10(a) to the Company's Current Report on Form 8-K filed on January 22, 2003, and incorporated by reference thereto).
  - 10(c) Employment Agreement dated January 1, 2003, by and between the Company and Mr. Nichols.
  - 10(d) Employment Agreement dated June 23, 2000, by and between the Company and Mr. Kleiman, as amended. (Filed as Exhibit 10 to the Company's Annual Report on Form 10-KSB for the fiscal year ended June 30, 2000 and incorporated by reference thereto).
  - 10(e) Consulting Agreement dated January 1, 2003 by and between the Company and Mr. Cremonese and his affiliate, Laboratory Innovation Company, Ltd., (Filed as Exhibit 10(b) to the Company's Current Report on Form 8-K filed on January 6, 2003, and incorporated by reference thereto).
- 21 Subsidiaries of the Registrant

Scientific Packaging Industries, Inc., a New York corporation, is a wholly-owned inactive subsidiary of the Company.
- 31.1 Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002.

## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

32.1 Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of Sarbanes-Oxley Act of 2002.

Report of Independent Certified Public Accountants

Board of Directors and Shareholders  
Scientific Industries, Inc. and subsidiary  
Bohemia, New York

We have audited the accompanying consolidated balance sheets of Scientific Industries, Inc. and subsidiary as of June 30, 2003 and 2002, and the related consolidated statements of income, shareholders' equity and cash flows for the years then ended. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Scientific Industries, Inc. and subsidiary as of June 30, 2003 and 2002, and the consolidated results of their operations and their consolidated cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

/s/ Nussbaum Yates & Wolpow, P.C.

---

Nussbaum Yates & Wolpow, P.C.  
Melville, New York

August 27, 2003

F-1

SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARY  
CONSOLIDATED BALANCE SHEETS  
JUNE 30, 2003 and 2002

ASSETS

Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

	2003	2002	
Current assets:			
Cash and cash equivalents	\$ 107,600	\$ 296,800	
Investment securities	695,400	481,900	
Trade accounts receivable, less allowance for doubtful accounts of \$7,400 in 2003 and 2002	409,600	276,000	
Inventories	582,200	679,100	
Prepaid expenses and other current assets	64,600	63,200	
	-----	-----	
Total current assets	1,859,400	1,797,000	
Investment securities	-	51,900	
Property and equipment, net	152,500	182,900	
Deferred taxes	113,600	106,600	
Intangible assets, less accumulated amortization of \$36,800 and \$31,200 in 2003 and 2002		15,500	6,500
Other	75,400	94,500	
	-----	-----	
Total assets	\$2,216,400	\$2,239,400	
	=====	=====	

LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:		
Accounts payable	\$ 58,100	\$ 84,400
Accrued expenses	126,300	181,200
	-----	-----
Total current liabilities	184,400	265,600
Deferred compensation	43,800	59,500
	-----	-----
Commitments and contingencies		
Shareholders' equity:		
Common stock, \$.05 par value; authorized 7,000,000 shares; issued 980,343 and 970,343 shares in 2003 and 2002	49,000	48,500
Additional paid-in capital	971,200	960,900
Accumulated other comprehensive income, unrealized holding gain on investment securities	300	1,000
Retained earnings	1,020,100	956,300
	-----	-----
	2,040,600	1,966,700
Less common stock held in treasury, at cost, 19,802 shares	52,400	52,400
	-----	-----
Total shareholders' equity	1,988,200	1,914,300
	-----	-----
Total liabilities and shareholders' equity	\$2,216,400	\$2,239,400

Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

=====

See notes to consolidated financial statements

F-2

SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARY  
CONSOLIDATED STATEMENTS OF INCOME  
YEARS ENDED JUNE 30, 2003 and 2002

	2003	2002
Net sales	\$3,257,100	\$3,457,300
Cost of sales	1,914,500	2,048,100
Gross profit	----- 1,342,600	----- 1,409,200
Operating expenses:		
General and administrative	791,700	854,900
Selling		216,000
Research and development	292,300	289,600
	-----	-----
		1,300,000
Income from operations	----- 42,600	----- 86,300
Other income (expense):		
Interest income		15,100
Other income (expense), net	( 5,400)	4,700
	-----	-----
		9,700
Income before income tax expense (benefit)	----- 52,300	----- 105,500
Income tax expense (benefit):		
Current	( 4,500)	33,300
Deferred	( 7,000)	( 5,000)
	-----	-----
	( 11,500)	28,300
Net income	----- \$ 63,800	----- 77,200
Net income per common share - basic	=====	=====
	\$ .07	\$ .08
Net income per common share - diluted	=====	=====
	\$ .06	\$ .08
	=====	=====

See notes to consolidated financial statements

F-3

SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARY  
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY  
YEARS ENDED JUNE 30, 2003 AND 2002

Accumulated

Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

	Common Stock		Additional	Other
	-----		Paid-in	Comprehensive
	Shares	Amount	Capital	Income (Loss)
	-----	-----	-----	-----
Balance, July 1, 2001	915,342	\$45,800	\$ 912,500	(\$ 5,000)
Net income	-	-	-	-
Other comprehensive gain:				
Unrealized holding gain				
arising during period	-	-	-	6,000
Comprehensive income	-	-	-	-
Exercise of stock options	55,000	2,700	43,400	-
Exercise of stock warrant	1	-	-	-
Income tax benefit of				
stock options exercised	-	-	5,000	-
Balance, June 30, 2002	970,343	48,500	960,900	1,000
Net income	-	-	-	-
Other comprehensive loss:				
Unrealized holding loss				
arising during period	-	-	-	( 700)
Comprehensive income	-	-	-	-
Exercise of stock options	10,000	500	6,100	-
Income tax benefit of				
stock options exercised	-	-	4,200	-
Balance, June 30, 2003	980,343	\$49,000	\$971,200	\$ 300

SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARY  
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (CONTINUED)  
YEARS ENDED JUNE 30, 2003 AND 2002

	Retained	Treasury Stock		Total
	Earnings	Shares	Amount	Shareholders'
	-----	-----	-----	Equity
	-----	-----	-----	-----
Balance, July 1, 2001	\$879,100	19,802	\$52,400	\$ 1,780,000
Net income	77,200	-	-	77,200
Other comprehensive gain:				
Unrealized holding gain				
arising during period	-	-	-	6,000
Comprehensive income	-	-	-	83,200
Exercise of stock options	-	-	-	46,100
Exercise of stock warrant	-	-	-	-

Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

Income tax benefit of stock options exercised	-	-	-	5,000
	-----	-----	-----	-----
Balance, June 30, 2002	956,300	19,802	52,400	1,914,300
	-----	-----	-----	-----
Net income	63,800	-	-	63,800
Other comprehensive loss:				
Unrealized holding loss arising during period	-	-	-	( 700)
				-----
Comprehensive income	-	-	-	63,100
				-----
Exercise of stock options	-	-	-	6,600
Income tax benefit of stock options exercised	-	-	-	4,200
	-----	-----	-----	-----
Balance, June 30, 2003	\$1,020,100	19,802	\$52,400	\$ 1,988,200
	=====	=====	=====	=====

See notes to consolidated financial statements

F-4

SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARY  
CONSOLIDATED STATEMENTS OF CASH FLOWS  
YEARS ENDED JUNE 30, 2003 AND 2002

	2003	2002
Operating activities:		
Net income	\$ 63,800	\$ 77,200
	-----	-----
Adjustments to reconcile net income to net cash provided by operating activities:		
Gain on sale of investments	( 800)	( 4,400)
Loss on disposal of property and equipment	6,400	-
Depreciation and amortization	65,400	65,300
Deferred income taxes	( 7,000)	( 5,000)
Income tax benefit of stock options exercised	4,200	5,000
Changes in assets and liabilities:		
Trade accounts receivable	( 133,600)	24,400
Inventories	96,900	( 102,700)
Prepaid expenses and other current assets	( 1,400)	8,500
Other assets	19,100	56,400
Accounts payable	( 26,300)	( 68,100)
Accrued expenses	( 54,900)	92,400
Deferred compensation	( 15,700)	( 14,500)
	-----	-----
Total adjustments	( 47,700)	57,300
	-----	-----
Net cash provided by operating activities	16,100	134,500

Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

Investing activities:		
Purchase of investment securities, available for sale	( 241,500)	( 138,300)
Purchase of investment securities, held to maturity	( 113,700)	( 308,200)
Redemption of investment securities, available for sale	80,000	156,500
Redemption of investment securities, held to maturity	110,600	175,000
Capital expenditures	( 63,800)	( 43,600)
Proceeds from sale of property and equipment	31,000	-
Purchase of intangible assets	( 14,500)	( 600)
	-----	-----
Net cash used in investing activities	( 211,900)	( 159,200)
	-----	-----
Financing activities, proceeds from exercise of stock options	6,600	46,100
	-----	-----
Net increase (decrease) in cash and cash equivalents	( 189,200)	21,400
Cash and cash equivalents, beginning of year	296,800	275,400
	-----	-----
Cash and cash equivalents, end of year	\$ 107,600	\$ 296,800
	=====	=====

Supplemental disclosures of cash flow information:

Cash paid for income taxes	\$ 29,800	\$ 6,500
	=====	=====

See notes to consolidated financial statements

F-5

SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARY  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS  
YEARS ENDED JUNE 30, 2003 AND 2002

1. Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Scientific Industries, Inc. and Scientific Packaging Industries, Inc., its inactive wholly-owned subsidiary (collectively referred to as the "Company"). All material intercompany balances and transactions have been eliminated.

Revenue Recognition

Sales are recorded when the goods are shipped to customers and title passes.

Cash and Cash Equivalents

## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.

### Accounts Receivable

In order to record the Company's accounts receivable at their net realizable value, the Company must assess their collectibility. A considerable amount of judgment is required in order to make this assessment, including an analysis of historical bad debts and other adjustments, a review of the aging of the Company's receivables, and the current creditworthiness of the Company's customers. The Company has recorded allowances for receivables which it considered uncollectible, including amounts for the resolution of potential credit and other collection issues such as disputed invoices, customer satisfaction claims and pricing discrepancies. However, depending on how such potential issues are resolved, or if the financial condition of any of the Company's customers was to deteriorate and their ability to make required payments became impaired, increases in these allowances may be required. The Company actively manages its accounts receivable to minimize credit risk. The Company does not obtain collateral for its accounts receivable.

### Investment Securities

Securities which the Company has the ability and positive intent to hold to maturity are carried at amortized cost. Substantially all held-to-maturity securities mature within one year. Securities available for sale are carried at fair value with unrealized gains or losses reported in a separate component of shareholders' equity. Realized gains or losses are determined based on the specific identification method.

F-6

SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARY  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)  
YEARS ENDED JUNE 30, 2003 AND 2002

1. Summary of Significant Accounting Policies (Continued)

#### Inventories

Inventories are stated at the lower of cost (first-in, first-out basis) or market.

#### Property and Equipment

Property and equipment are stated at cost. Depreciation of computer equipment, machinery and equipment and furniture and fixtures is provided for primarily by the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized by the straight-line method over the term of the related lease or the estimated useful lives of the assets, whichever is shorter.

#### Intangible Assets

Intangible assets consist of patents and trademarks being



## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

amortized on a straight-line basis over five years. Amortization expense of intangible assets for the years ended June 30, 2003 and 2002 was \$6,000. Estimated future annual amortization expense is expected to be similar.

### Asset Impairment

The Company reviews its long-lived assets annually to determine whether facts and circumstances exist which indicate that the carrying amount of assets may not be recoverable or the useful life is shorter than originally estimated. The Company assesses the recoverability of its assets by comparing the projected undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. If assets are determined to be recoverable, but the useful lives are shorter than originally estimated, the net book value of the assets is depreciated over the newly determined remaining useful lives.

### Income Taxes

The Company accounts for income taxes according to the provisions of Statement of Financial Accounting Standards (SFAS) No. 109, "Accounting for Income Taxes". Under the liability method specified by SFAS 109, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. Deferred tax expense is the result of changes in deferred tax assets and liabilities. Deferred income taxes result principally from the timing of the deductibility of the rent accrual, inventory adjustments, deferred compensation, the use of accelerated methods of depreciation and amortization for tax purposes, and tax credit carryforwards.

F-7

SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARY  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)  
YEARS ENDED JUNE 30, 2003 AND 2002

1. Summary of Significant Accounting Policies (Continued)

#### Stock Compensation Plan

During the year ended June 30, 2003, the Company established a new ten-year stock option plan (the "2002 Plan") which provides for the future grant of options to purchase up to 100,000 shares of the Company's Common Stock, par value \$.05 per share ("Common Stock"), plus to the extent that options previously granted under the 1992 Stock Option Plan of the Company (the "Prior Plan") expire or terminate for any reason without having been exercised, then options exercisable for that same number of shares of Common Stock, up to a maximum of one hundred sixty thousand (161,000) shares, may be granted pursuant to the 2002 Plan. The 2002 Plan provides for the granting of incentive or non-incentive stock options as defined in the 2002 Plan. Incentive stock options may be granted to employees at

## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

an exercise price equal to 100% (or 110% if the optionee owns directly or indirectly more than 10% of the outstanding voting stock) of the fair market value of the shares of Common Stock on the date of the grant. Non-incentive stock options shall be granted at an exercise price not less than 85% of the fair market value of the shares of Common Stock on the date of grant. The 2002 Plan also stipulates that none of Messrs. Joseph I. Kesselman, Arthur M. Borden, Roger B. Knowles, Lowell A. Kleiman and James S. Segasture shall be eligible to receive option grants under the 2002 Plan. However the Prior Plan provided that each non-employee member of the Board of Directors be granted, annually commencing March 1993, for a period of four years, a ten-year option to purchase 3,000 shares of Common Stock at the fair market value on the date of grant and commencing annually in December 1997, for as long a director, a ten-year option to purchase 4,000 shares of Common Stock at the fair market value on the date of grant. No options have been granted to directors of the Company since December 2001. The options expire at various dates through October 2012. At June 30, 2003, 93,000 shares of Common Stock were available for grant under the 2002 Plan plus 15,000 shares which expired under the Prior Plan.

The Company has elected to account for its employee stock options under APB Opinion No. 25, "Accounting for Stock Issued to Employees," under which no compensation expense is recognized for options granted under fixed plans when the option price is not less than the fair market value of the underlying common stock on the date of grant. Pro forma information regarding net income and earnings per share, however, is required under Statement of Financial Accounting Standards No. 123, "Accounting for Stock-Based Compensation," (SFAS No. 123) for entities continuing to apply APB No. 25. For disclosure purposes, the Company has estimated the fair value of its employee stock options on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions used for stock options granted in 2003 and 2002, respectively:

F-8

SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARY  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)  
YEARS ENDED JUNE 30, 2003 AND 2002

1. Summary of Significant Accounting Policies (Continued)

Stock Compensation Plan (Continued)

	2003	2002
Expected life (in years)	10	10
Risk-free interest rate	4.39%	5.54%
Expected volatility	35.74%	36.68%
Dividend yield	0.00%	0.00%

Under the above model, the total value of stock options granted in 2003 and 2002 was \$4,800 and \$22,600 respectively, which would be amortized ratably on a pro forma basis over the related vesting periods of three years. Had compensation cost been determined based upon the fair value of the stock options at grant date for all awards, the Company's net income and earnings per share would have been

## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

reduced to the pro forma amounts indicated below:

	2003	2002
Net income:		
As reported	\$63,800	\$77,200
Pro forma	\$63,000	\$49,600
Basic earnings per share:		
As reported	\$ .07	\$ .08
Pro forma	\$ .07	\$ .05
Diluted earnings per share:		
As reported	\$ .06	\$ .08
Pro forma	\$ .06	\$ .05
Stock-based employee compensation cost, net of related tax effects, included in the determination of net income as reported		
\$ -0-	\$ -0-	

The SFAS No. 123 method of accounting does not apply to options granted prior to January 1, 1995 and, accordingly, the resulting pro forma compensation cost may not be representative of that to be expected in future years.

F-9

SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARY  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)  
YEARS ENDED JUNE 30, 2003 AND 2002

1. Summary of Significant Accounting Policies (Continued)

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes. The accounting estimates that require management's most difficult and subjective judgments include the assessment of recoverability of long-term assets and the recognition and measurement of income tax assets and liabilities. The actual results experienced by the Company may differ materially from management's estimates.

Net Income Per Common Share

Basic net income per common share is computed by dividing net income by the weighted-average number of shares outstanding. Diluted net income per share includes the dilutive effect of stock options and warrants.

Recent Accounting Pronouncements

Recent accounting pronouncements not reflected herein do not have a material effect on the Company's financial statements.

2. Line of Business and Concentrations

## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

The Company is engaged in the manufacturing and marketing of equipment for research in university, hospital and industrial laboratories. The Company believes that it has only one reportable segment. Approximately 86% in 2003 and 92% in 2002 of sales are generated from the Vortex-Genie (registered trademark) 2 mixer and related accessories.

Certain information relating to the Company's export sales and principal customers is as follows:

	2003	2002
Export sales (principally Europe and Asia)	\$1,583,700	\$1,522,900
Customers in excess of 10% of net sales:		
Largest in 2003 and 2002	867,000	1,141,100
Second largest in 2003 and 2002	488,600	337,100

Accounts receivable from these two customers amounted to approximately 39% and 37% of total accounts receivable at June 30, 2003 and 2002.

F-10

SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARY  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)  
YEARS ENDED JUNE 30, 2003 AND 2002

### 3. Investment Securities

Details as to investment securities are as follows:

	Gross Cost or Amortized Cost	Fair Value	Unrealized Holding Gain (Loss)
At June 30, 2003:			
Available for sale:			
Equity securities	\$ 20,700	\$ 18,800	(\$1,900)
Mutual funds	511,000	513,200	2,200
	-----	-----	-----
	\$531,700	\$532,000	\$ 300
	=====	=====	
Held-to-maturity:			
State and municipal bonds, due in one year or less	\$163,400	\$163,600	\$ 200
	=====	=====	
	Gross Cost or Amortized Fair Cost	Value	Unrealized Holding Gain (Loss)
At June 30, 2002:			
Available for sale:			

Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

Equity securities	\$ 20,700	\$ 18,500	(\$2,200)
Mutual funds	348,800	352,000	3,200
	-----	-----	
		\$369,500	\$370,500
	=====	=====	\$1,000
Held-to-maturity:			
State and municipal bonds, due in one year or less	\$111,400	\$111,200	(\$ 200)
State and municipal bonds, due September 15, 2003	51,900	51,900	-
	-----	-----	-----
		\$163,300	\$163,100
	=====	=====	(\$ 200)

F-11

SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARY  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)  
YEARS ENDED JUNE 30, 2003 AND 2002

4. Inventories

	2003	2002
Raw materials	\$532,100	\$445,700
Work-in-process	4,700	102,500
Finished goods	45,400	130,900
	-----	-----
	\$582,200	\$679,100
	=====	=====

5. Property and Equipment, Net

	Useful Lives (Years)	2003	2002
Computer equipment	3 - 5	\$167,000	\$196,600
Machinery and equipment	3 - 7	272,200	256,000
Furniture and fixtures	4 - 10	70,800	71,500
Leasehold improvements	1 - 8	35,200	34,900
		-----	-----
		545,200	559,000
Less accumulated depreciation and amortization		392,700	376,100
		-----	-----
		\$152,500	\$182,900
		=====	=====

6. Bank Line of Credit

The Company has a \$200,000 secured bank line of credit collateralized by all the assets of the Company. The credit line expires on November 1, 2003 and bears interest at prime plus 1%. The Company did not utilize this credit line during the years ended June 30, 2003 and 2002. To support the line of credit available, the Company is required to maintain 20% of the credit line in average monthly balances.

F-12

# Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

## SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED) YEARS ENDED JUNE 30, 2003 AND 2002

### 7. Employee Benefit Plan

The Company has a 401(k) profit sharing plan for all eligible employees as defined in the Plan. The Plan provides for voluntary employee salary contributions from 1% to 15% not to exceed the statutory limitation provided by the Internal Revenue Code. The Company shall match 50% of each participant's salary deferral election, up to a maximum amount for each participant of 2% of their compensation. The Company also has the option to make an additional profit sharing contribution to the Plan. Employer matching contributions to the Plan amounted to \$10,600 in 2003 and \$16,500 in 2002.

### 8. Commitments and Contingencies

#### Lease

The Company is obligated through December 2004 under a noncancelable operating lease for its premises, which requires minimum annual rentals and certain other expenses, including real estate taxes and insurance. Rental expense under the lease amounted to approximately \$237,400 in 2003 and \$232,700 in 2002.

As of June 30, 2003, the Company's approximate future minimum rental payments under the above lease are as follows:

Fiscal Years	
2004	\$239,800
2005	122,900

In accordance with generally accepted accounting principles, the future minimum annual rental expense, computed on a level basis, will be approximately \$223,100 under the terms of the lease. Accrued rent, payable in future years, amounted to \$28,000 and \$33,000 at June 30, 2003 and 2002.

#### Employment Contracts

The Company had an employment contract (which expired June 30, 2002) with its former President. On August 29, 2002, the Company decided to terminate his employment. The contract provided for an annual salary of \$160,000 and also granted the President a five-year option to purchase 10,000 shares of common stock at \$1.50 per share which expired prior to exercise.

F-13

## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

### 8. Commitments and Contingencies (Continued)

#### Employment Contracts (Continued)

Pursuant to the employment contract, the former President chose that a portion of compensation earned in prior years be deferred to future years. The deferred amounts are to be placed in a separate investment account and all earnings and losses thereon are for his benefit. As of June 30, 2003 and 2002, \$58,400 and \$74,400 was segregated into such an account and is included as an asset. The balance due to him is payable out of (but not secured by) the account, in five equal annual installments as adjusted by market fluctuations commencing after the termination of employment. Accordingly, \$14,600 has been classified as a short-term asset and liability and \$43,800 as a long-term asset and liability at June 30, 2003. For the year ended June 30, 2003, \$12,700 was paid to the former President.

During the year ended June 30, 2003, the Company entered into employment agreements with both its current President and Executive Vice President for two-year periods expiring December 31, 2004. The agreements with its President and Vice President provide for a base salary for the first year of \$100,000 and \$95,000, respectively, with the salary for calendar 2004 to be determined by the Board of Directors, but to be not less than the base salary. The agreements also provide for discretionary performance-related annual bonuses.

#### Other

A financial advisor employed by the Company pursuant to an engagement letter that was not extended by the Company beyond its expiration date of March 31, 2002 asserted a claim against the Company in April 2002 in the amount of \$125,000 for alleged services rendered to the Company that were alleged to be outside the scope of the letter. The Company denies engaging the financial advisor for any services outside the scope of the engagement letter or that any amounts are owing to the advisor. The Company's counsel has advised the Company that based on its review of the engagement letter and the Company's denial, it is unlikely that the financial advisor will prevail if it institutes a legal proceeding. Accordingly, no provision for loss has been recorded by the Company at June 30, 2003.

During the year ended June 30, 2003, the Company entered into a two-year consulting agreement through December 31, 2004 with a member of its Board of Directors for marketing consulting services. The agreement provides that the director will be paid a monthly fee of \$3,000 for a certain number of consulting days as defined in the agreement.

F-14

SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARY  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)  
YEARS ENDED JUNE 30, 2003 AND 2002

### 9. Income Taxes

## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

Income taxes (benefit) for 2003 and 2002 were different from the amounts computed by applying the Federal income tax rate to the income before income taxes due to the following:

		2003		2002	
		-----	% of	-----	% of
		Amount	Pretax	Amount	Pretax
			Income		Income
Computed "expected" income tax	\$17,800		34.0%	\$35,900	34.0%
Research and development credits	( 18,600)	(36.0 )		( 18,300)	(17.3)
Other		( 10,700)	(20.0 )	10,700	10.1
		-----		-----	
Actual income taxes (benefit)	(\$11,500	(22.0 )		\$28,300	26.8%
		=====		=====	

Deferred tax assets and liabilities consist of the following:

		2003		2002
Deferred tax assets:				
Amortization of intangibles	\$ 7,900		\$ 8,100	
Deferred compensation	17,500			25,300
Rent accrual	8,400			11,200
Tax credit carryforwards	77,500			56,100
Other	15,700			18,600
		-----		-----
			127,000	119,300
Deferred tax liability:				
Depreciation of property and equipment	( 13,400)		( 12,700)	
		-----		-----
Net deferred tax assets	\$ 113,600		\$ 106,600	
		=====		=====

At June 30, 2003, the Company had tax credit carryforwards of approximately \$77,500 expiring in 2019 through 2023.

F-15

SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARY  
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)  
 YEARS ENDED JUNE 30, 2003 AND 2002

10. Stock Options and Warrant

Option activity is summarized as follows:

		Fiscal 2003		Fiscal 2002
		Weighted-	Weighted-	
		Average	Average	
		Exercise	Exercise	
		Price	Price	
	Shares	Price	Shares	Price
	-----	-----	-----	-----
Shares under option:				
Outstanding at beginning				
of year	165,000	\$1.39	225,000	\$1.19
Granted	7,000	\$1.25	16,000	2.40
Exercised	( 10,000)	.66	( 31,000)	1.22



Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

Expired	-	-	( 20,000)	1.41
Forfeited	( 15,000)	1.06	( 25,000)	.38
	-----		-----	
Outstanding at end of year	147,000	\$1.47	165,000	\$1.39
	=====		=====	
Options exercisable at year-end	140,000	\$1.48	165,000	\$1.39
	=====		=====	
Weighted average fair value per share of options granted during fiscal 2003 and 2002		\$ .69		\$1.41
		=====		=====

The following table summarizes information about the options outstanding at June 30, 2003:

Options Outstanding			Options Exercisable		
Range of Exercise Prices	Number Outstanding	Weighted-Average Remaining Contractual Life (Years)	Weighted-Average Exercise Price	Number Outstanding	Weighted-Average Exercise Price
\$1.25 - \$2.40	103,000	5.50	\$1.74	96,000	\$1.77
\$.50 - \$.94	44,000	4.26	.85	44,000	.85

F-16

SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARY  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)  
YEARS ENDED JUNE 30, 2003 AND 2002

10. Stock Options and Warrant (Continued)

During the year ended June 30, 2003, three directors and an officer exercised options under the Prior Plan to acquire a total of 10,000 shares at \$.50 to \$.94 per share. During the year ended June 30, 2002, four directors exercised options under the Prior Plan to acquire a total of 31,000 shares at \$.50 to \$2.00 per share.

In addition, in February 1992, the Company granted to four non-employee members of the board of directors, ten-year options for each to purchase 12,000 shares of Common Stock, at an exercise price of \$.35, not covered under either Plan. The options were exercisable one-third within one year from the date of grant and one-third in each of the following two years. In March 1993, three directors each exercised 8,000 options. During the year ended June 30, 2002, the remaining 24,000 options were exercised by the directors.

The Company has a stock purchase warrant outstanding covering 17,391 shares of the Company's common stock issued during 2001 for services. The warrant has an exercise price of \$1.4375 per share and expires on February 5, 2006. During the year ended

## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

June 30, 2003, none of the warrants were exercised. During the year ended June 30, 2002, one share was issued upon warrant exercise.

### 11. Net Income Per Common Share

Net income per common share data was computed as follows:

	2003	2002
Net income	\$ 63,800	\$ 77,200
	=====	=====
Weighted average common shares outstanding	955,766	930,704
Effect of dilutive securities, stock options and warrant	38,343	79,175
	-----	-----
Weighted average dilutive common shares outstanding	994,109	1,009,879
	=====	=====
Net income per common share - basic	\$ .07	\$ .08
	=====	=====
Net income per common share - diluted	\$ .06	\$ .08
	=====	=====

F-17

SCIENTIFIC INDUSTRIES, INC. & SUBSIDIARY  
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)  
 YEARS ENDED JUNE 30, 2003 AND 2002

### 11. Net Income Per Common Share (Continued)

Unexercised employee stock options to purchase 56,000 and 59,000 shares of common stock at \$1.875 to \$2.40 per share were outstanding as of June 30, 2003 and 2002, respectively, but were not included in the foregoing potential computation because the options' exercise price was greater than the average market price of the Company's common stock.

### 12. Fair Value of Financial Instruments

The financial statements include various estimated fair value information as of June 30, 2003 and 2002, as required by Statement of Financial Accounting Standards 107, "Disclosure about Fair Value of Financial Instruments." Such information, which pertains to the Company's financial instruments, is based on the requirements set forth in that statement and does not purport to represent the aggregate net fair value of the Company. The following methods and assumptions were used to estimate the fair value of each class of financial instruments for which it is practicable to estimate that value.

The carrying value of cash and cash equivalents and investment securities approximates fair market value because of the short maturity of those instruments.

## Edgar Filing: SCIENTIFIC INDUSTRIES INC - Form 10KSB

The following table provides summary information on the fair value of significant financial instruments included in the financial statements:

	2003		2002	
	Estimated Carrying Fair Amount Value	Estimated Carrying Fair Amount Value	Estimated Carrying Fair Amount Value	Estimated Carrying Fair Amount Value
	-----	-----	-----	-----
<b>Assets:</b>				
Cash and cash equivalents	\$107,600	\$107,600	\$296,800	\$296,800
Investment securities (Note 3)	\$695,400	\$695,600	533,800	533,600

F-18